tradingkey.logo

PharmaCyte Biotech Inc

PMCB
0.765USD
-0.005-0.68%
收盘 12/24, 13:00美东报价延迟15分钟
5.20M总市值
亏损市盈率 TTM

PharmaCyte Biotech Inc

0.765
-0.005-0.68%

关于 PharmaCyte Biotech Inc 公司

PharmaCyte Biotech, Inc. is a biotechnology company, which is focused on developing cellular therapies for cancer based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC) will be developed. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used as a means to produce various biologically active molecules. The technology is intended to result in the formation of pinhead-sized cellulose-based porous capsules in which genetically modified live human cells can be encapsulated and maintained. In a laboratory setting, this proprietary live cell encapsulation technology has been shown to create a micro-environment in which encapsulated cells survive and flourish.

PharmaCyte Biotech Inc简介

公司代码PMCB
公司名称PharmaCyte Biotech Inc
上市日期Sep 11, 2003
CEOSilverman (Joshua N)
员工数量2
证券类型Ordinary Share
年结日Sep 11
公司地址3960 Howard Hughes Parkway, Suite 500
城市LAS VEGAS
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编89169
电话19175952850
网址https://pharmacyte.com/
公司代码PMCB
上市日期Sep 11, 2003
CEOSilverman (Joshua N)

PharmaCyte Biotech Inc公司高管

名称
名称/职务
职务
持股
持股变动
Mr. Jonathan L. Schechter
Mr. Jonathan L. Schechter
Independent Director
Independent Director
50.00K
--
Mr. Carlos A. Trujillo, CPA
Mr. Carlos A. Trujillo, CPA
Chief Financial Officer
Chief Financial Officer
10.40K
--
Dr. Michael M. Abecassis, M.D.
Dr. Michael M. Abecassis, M.D.
Independent Director
Independent Director
--
--
Mr. Wayne R. Walker
Mr. Wayne R. Walker
Independent Director
Independent Director
--
--
Mr. Robert Weinstein
Mr. Robert Weinstein
Independent Director
Independent Director
--
--
Mr. Joshua N. (Josh) Silverman
Mr. Joshua N. (Josh) Silverman
Interim Chairman of the Board, Interim Chief Executive Officer and Interim President
Interim Chairman of the Board, Interim Chief Executive Officer and Interim President
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Jonathan L. Schechter
Mr. Jonathan L. Schechter
Independent Director
Independent Director
50.00K
--
Mr. Carlos A. Trujillo, CPA
Mr. Carlos A. Trujillo, CPA
Chief Financial Officer
Chief Financial Officer
10.40K
--
Dr. Michael M. Abecassis, M.D.
Dr. Michael M. Abecassis, M.D.
Independent Director
Independent Director
--
--
Mr. Wayne R. Walker
Mr. Wayne R. Walker
Independent Director
Independent Director
--
--
Mr. Robert Weinstein
Mr. Robert Weinstein
Independent Director
Independent Director
--
--
Mr. Joshua N. (Josh) Silverman
Mr. Joshua N. (Josh) Silverman
Interim Chairman of the Board, Interim Chief Executive Officer and Interim President
Interim Chairman of the Board, Interim Chief Executive Officer and Interim President
--
--

收入明细

由于公司未披露,未能获取相关数据
由于公司未披露,未能获取相关数据
业务
地区
由于公司未披露,未能获取相关数据

股东统计

更新时间: 12月14日 周日
更新时间: 12月14日 周日
持股股东
股东类型
持股股东
持股股东
占比
Intracoastal Capital, L.L.C.
5.20%
Schechter (Jonathan L)
1.31%
Geode Capital Management, L.L.C.
1.25%
Equitec Proprietary Markets, LLC
0.82%
Asher (Daniel B)
0.82%
其他
90.61%
持股股东
持股股东
占比
Intracoastal Capital, L.L.C.
5.20%
Schechter (Jonathan L)
1.31%
Geode Capital Management, L.L.C.
1.25%
Equitec Proprietary Markets, LLC
0.82%
Asher (Daniel B)
0.82%
其他
90.61%
股东类型
持股股东
占比
Corporation
5.20%
Individual Investor
3.56%
Investment Advisor
1.58%
Investment Advisor/Hedge Fund
1.44%
Hedge Fund
1.25%
Research Firm
0.02%
其他
86.96%

机构持股

更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
61
457.38K
6.73%
-604.80K
2025Q2
66
1.28M
18.72%
-522.91K
2025Q1
71
1.30M
18.90%
-631.78K
2024Q4
75
1.52M
21.80%
-704.25K
2024Q3
81
1.75M
23.16%
-1.87M
2024Q2
84
1.91M
21.34%
-3.77M
2024Q1
81
1.85M
20.70%
-3.82M
2023Q4
82
1.98M
21.84%
-3.87M
2023Q3
81
2.90M
23.35%
-2.45M
2023Q2
83
2.99M
16.94%
-4.58M
查看更多

股东持股明细

名称
持股数
占比
持股变动
变动比例
公告日期
Intracoastal Capital, L.L.C.
527.38K
1.12%
--
--
Dec 31, 2024
Schechter (Jonathan L)
50.00K
0.11%
--
--
Sep 15, 2025
Geode Capital Management, L.L.C.
126.60K
0.27%
-12.33K
-8.88%
Jun 30, 2025
Equitec Proprietary Markets, LLC
82.73K
0.18%
--
--
Jun 30, 2025
Asher (Daniel B)
82.73K
0.18%
--
--
Dec 31, 2024
Renaissance Technologies LLC
49.80K
0.11%
+300.00
+0.61%
Jun 30, 2025
The Vanguard Group, Inc.
194.45K
0.41%
-71.00
-0.04%
Jun 30, 2025
Silverman (Joshua N.)
50.00K
0.11%
--
--
Sep 15, 2025
Schonfeld Strategic Advisors LLC
26.20K
0.06%
+700.00
+2.75%
Jun 30, 2025
查看更多

持股ETF

更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
iShares Micro-Cap ETF
0%
Dimensional US Core Equity 1 ETF
0%
iShares Micro-Cap ETF
占比0%
Dimensional US Core Equity 1 ETF
占比0%

分红派息

近5年累计派现 0.00 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据

拆合股

公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据

常见问题

PharmaCyte Biotech Inc的前五大股东是谁?

PharmaCyte Biotech Inc 的前五大股东如下:
Intracoastal Capital, L.L.C.持有股份:527.38K,占总股份比例:1.12%。
Schechter (Jonathan L)持有股份:50.00K,占总股份比例:0.11%。
Geode Capital Management, L.L.C.持有股份:126.60K,占总股份比例:0.27%。
Equitec Proprietary Markets, LLC持有股份:82.73K,占总股份比例:0.18%。
Asher (Daniel B)持有股份:82.73K,占总股份比例:0.18%。

PharmaCyte Biotech Inc的前三大股东类型是什么?

PharmaCyte Biotech Inc 的前三大股东类型分别是:
Intracoastal Capital, L.L.C.
Schechter (Jonathan L)
Geode Capital Management, L.L.C.

有多少机构持有PharmaCyte Biotech Inc(PMCB)的股份?

截至2025Q3,共有61家机构持有PharmaCyte Biotech Inc的股份,合计持有的股份价值约为457.38K,占公司总股份的6.73%。与2025Q2相比,机构持股有所增加,增幅为-11.99%。

哪个业务部门对PharmaCyte Biotech Inc的收入贡献最大?

在--,--业务部门对PharmaCyte Biotech Inc的收入贡献最大,创收--,占总收入的--%。
KeyAI